Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Hypoxia was identified as a microenvironmental component of solid tumours over 60 years ago and was immediately recognised as a potential barrier to therapy through the reliance of radiotherapy on oxygen to elicit maximal cytotoxicity. Over the last two decades both clinical and experimental studies have markedly enhanced our understanding of how hypoxia influences cellular behaviour and therapy response. Furthermore, they have confirmed early assumptions that low oxygenation status in tumours is an exploitable target in cancer therapy. Generally such approaches will be more beneficial to patients with hypoxic tumours, necessitating the use of biomarkers that reflect oxygenation status. Tissue biomarkers have shown utility in many studies. Further significant advances have been made in the non-invasive measurement of tumour hypoxia with positron emission tomography, magnetic resonance imaging and other imaging modalities. Here, we describe the complexities of defining and measuring tumour hypoxia and highlight the therapeutic approaches to combat it.

Original publication

DOI

10.1016/j.clon.2014.02.002

Type

Journal article

Journal

Clin Oncol (R Coll Radiol)

Publication Date

05/2014

Volume

26

Pages

277 - 288

Keywords

Hypoxia, hypoxia-activated prodrugs, imaging, oxygen, radiation, Animals, Antineoplastic Agents, Cell Hypoxia, DNA Repair, Drug Resistance, Neoplasm, Humans, Hypoxia-Inducible Factor 1, Magnetic Resonance Imaging, Neoplasms, Oxygen, Positron-Emission Tomography, Prodrugs, Signal Transduction